CA2359776C - Procedes de prevention et de traitement de maladies dues a une reponse inflammatoire induite par la substance p endogene, par l'utilisation d'anticorps anti-substance p - Google Patents

Procedes de prevention et de traitement de maladies dues a une reponse inflammatoire induite par la substance p endogene, par l'utilisation d'anticorps anti-substance p Download PDF

Info

Publication number
CA2359776C
CA2359776C CA2359776A CA2359776A CA2359776C CA 2359776 C CA2359776 C CA 2359776C CA 2359776 A CA2359776 A CA 2359776A CA 2359776 A CA2359776 A CA 2359776A CA 2359776 C CA2359776 C CA 2359776C
Authority
CA
Canada
Prior art keywords
substance
subject
antibodies
antibody fragments
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2359776A
Other languages
English (en)
Other versions
CA2359776A1 (fr
Inventor
Ralph A. Tripp
Larry J. Anderson
Deborah D. Moore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CA2359776A1 publication Critical patent/CA2359776A1/fr
Application granted granted Critical
Publication of CA2359776C publication Critical patent/CA2359776C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des procédés de prévention ou de traitement d'un trouble chez un sujet ayant une réponse inflammatoire à une maladie ou à un syndrome, ladite réponse inflammatoire étant induite par la substance P endogène. Ces procédés comprennent l'administration au sujet d'une quantité efficace d'un point de vue pharmaceutique d'anticorps anti-substance P, ou de fragments d'anticorps anti-substance P, tels que les fragments F(ab)¿2?, ce qui permet d'inhiber l'activité de la substance P endogène. L'inhibition de l'activité de la substance P endogène chez le sujet provoque la réduction des taux de cytokines produites par les lymphocytes T du sujet, l'altération des signaux qui commandent la réponse inflammatoire à l'infection, ainsi que la réduction de l'inflammation induite par la cytokine. Le virus syncytal respiratoire est un exemple d'agent responsable d'une infection provoquant fréquemment un trouble dû à une réaction inflammatoire à une infection induite par la substance P endogène. En général, on administre à un mammifère une dose d'environ 0,001 mg à environ 10 g d'anticorps anti-substance P, ou de fragments d'anticorps anti-substance P, par kilogramme de poids corporel et par jour, la dose préférée étant comprise entre environ 1 mg et environ 1000 mg d'anticorps anti-substance P, ou de fragments d'anticorps anti-substance P, par kilogramme de poids corporel et par jour.
CA2359776A 1999-01-22 2000-01-14 Procedes de prevention et de traitement de maladies dues a une reponse inflammatoire induite par la substance p endogene, par l'utilisation d'anticorps anti-substance p Expired - Fee Related CA2359776C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11683599P 1999-01-22 1999-01-22
US60/116,835 1999-01-22
PCT/US2000/001032 WO2000043040A1 (fr) 1999-01-22 2000-01-14 Procedes de prevention et de traitement de maladies dues a une reponse inflammatoire induite par la substance p endogene, par l'utilisation d'anticorps anti-substance p

Publications (2)

Publication Number Publication Date
CA2359776A1 CA2359776A1 (fr) 2000-07-27
CA2359776C true CA2359776C (fr) 2010-08-03

Family

ID=22369522

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2359776A Expired - Fee Related CA2359776C (fr) 1999-01-22 2000-01-14 Procedes de prevention et de traitement de maladies dues a une reponse inflammatoire induite par la substance p endogene, par l'utilisation d'anticorps anti-substance p

Country Status (4)

Country Link
EP (1) EP1638603A1 (fr)
AU (1) AU770737B2 (fr)
CA (1) CA2359776C (fr)
WO (1) WO2000043040A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102835A2 (fr) 2000-11-21 2002-12-27 New England Medical Center Nouveaux composes antimicrobiens
WO2005100986A1 (fr) * 2004-04-15 2005-10-27 Bayer Healthcare Ag Diagnostics et methodes therapeutiques pour des maladies associees au recepteur de la tachykinine (tacr1)
US7544365B2 (en) * 2006-12-14 2009-06-09 The Hospital For Sick Children TRPV1+ sensory neurons control of β-cells stress and islet inflammation in diabetes
WO2009055711A2 (fr) 2007-10-25 2009-04-30 Trellis Bioscience, Inc. Anticorps de protéine g anti-rsv

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016547A1 (fr) * 1991-03-15 1992-10-01 The Children's Medical Center Corporation Controle des reponses a mediation par recepteurs nk-1 et diagnostiques associees
GB9505692D0 (en) * 1995-03-21 1995-05-10 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
EP1638603A1 (fr) 2006-03-29
WO2000043040A1 (fr) 2000-07-27
AU770737B2 (en) 2004-03-04
CA2359776A1 (fr) 2000-07-27
AU2414600A (en) 2000-08-07

Similar Documents

Publication Publication Date Title
KR101317264B1 (ko) 톨 유사 수용체 3 길항제, 방법 및 용도
EP1212088B1 (fr) Utilisation des anticorps contre le virus de la rubeole dans le traitement de symptomes de troubles du systeme nerveux central
US20060159655A1 (en) Treating immunological disorders using agonists of interleukin-21 / interleukin-21 receptor
US20080044409A1 (en) Inflammatory mediator antagonists
JP4991314B2 (ja) Ｍｓｒｖ／ｈｅｒｖ−ｗと関連した症状を治療するための組成物
CA2081479A1 (fr) Anticorps chimeriques humanises anti-icam-1, leurs modes de preparation et leur usage
RU2607022C2 (ru) Способы и композиции для лечения волчанки
Nardelli et al. Association of CD4+ CD25+ T cells with prevention of severe destructive arthritis in Borrelia burgdorferi-vaccinated and challenged gamma interferon-deficient mice treated with anti-interleukin-17 antibody
JP2003535909A (ja) グラチラマー・アセテートに対する抗体による中枢神経系疾患の治療
MXPA98000760A (en) Methods for the treatment of asthma allergy
JPH07506091A (ja) 喘息の処置
CA2437963A1 (fr) Molecules de liaison therapeutiques
EP3082863B1 (fr) Anticorps spécifiques dirigés contre l'alpha-énolase et méthode d'utilisation dans des maladies immunitaires
JP2002538170A (ja) 喘息の治療における抗−ＴＮＦα抗体
US20230382978A1 (en) Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
CN113574071A (zh) 用于治疗自身抗体介导的自身免疫疾病的抗-cd38抗体及其药物组合物
CA2359776C (fr) Procedes de prevention et de traitement de maladies dues a une reponse inflammatoire induite par la substance p endogene, par l'utilisation d'anticorps anti-substance p
Sitaraman et al. Interleukin-12 enhances clinical experimental autoimmune myasthenia gravis in susceptible but not resistant mice
US7101547B1 (en) Method for the prevention and treatment of diseases caused by an inflammatory response mediated by endogenous substance P by using anti-substance P antibodies
JP2023523096A (ja) 急性呼吸促迫症候群を治療するための組成物および方法
Tüzün et al. Genetic evidence for the involvement of Fcγ receptor III in experimental autoimmune myasthenia gravis pathogenesis
CA2548502A1 (fr) Methodes et compositions relatives a un antagoniste du ccr5, et inflammation induite par ifn-.gamma. et il-13
Capron et al. IgE and inflammatory cells
US11702470B2 (en) Use of CXCL13 binding molecules to promote peripheral nerve regeneration
KR20230142834A (ko) 항-cd38 항체 및 이의 용도

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160114